Genentech, a unit of Roche Holding AG (RHHBY), on Monday reported positive top-line results from its Phase III ALLEGORY study evaluating Gazyva in adults with systemic lupus erythematosus (SLE) receiving standard therapy.
The study met its primary endpoint showing a higher proportion of patients achieving at least four-point improvement in the SLE Responder Index 4 (SRI-4) at 52 weeks compared with standard therapy alone.
SRI is a tool used to assess changes in disease severity, symptoms, and physical condition to determine treatment effectiveness in controlling disease activity.
No new safety signals were identified, and safety profile was in line with the established clinical experience for Gazyva.
Gazyva is also being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.